Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19
Status:
Completed
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
The efficacy of treating COVID-19 infection by using Sofosbuvir/Ledipasvir and Nitazoxanide
will be examined. Included patients will be into 3 groups. The 1st group will receive
Sofosbuvir/Ledipasvir plus the standard care treatment (SCT). The 2nd group will take
Nitazoxanide and SCT, while the 3rd group will receive only SCT. Then the clinical
improvement and the rate of PCR change from positive to negative will be evaluated in each
group.
Phase:
Phase 4
Details
Lead Sponsor:
Assiut University
Collaborator:
Helwan University
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Nitazoxanide Sofosbuvir